Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial

被引:48
|
作者
Gault, Emma Jane [1 ]
Perry, Rebecca J. [1 ]
Cole, Tim J. [2 ]
Casey, Sarah [3 ]
Paterson, Wendy F. [1 ]
Hindmarsh, Peter C. [4 ]
Betts, Peter [5 ]
Dunger, David B. [6 ]
Donaldson, Malcolm D. C. [1 ]
机构
[1] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland
[2] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England
[3] Royal Hosp Sick Children, Dept Clin Trials, Dept Pharm, Glasgow G3 8SJ, Lanark, Scotland
[4] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England
[5] Southampton Univ Hosp NHS Trust, Dept Paediat, Southampton, Hants, England
[6] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England
来源
关键词
GROWTH-HORMONE TREATMENT; ESTROGEN REPLACEMENT; GIRLS; THERAPY; MULTICENTER; NORMALIZATION; MANAGEMENT; STATURE; AGE;
D O I
10.1136/bmj.d1980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Design Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. Participants Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week). Interventions Participants were randomised to oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of ovarian failure at 12 years were further randomised to oral ethinylestradiol (year 1, 2 mu g daily; year 2, 4 mu g daily; year 3, 4 months each of 6, 8, and 10 mu g daily) or placebo; participants who received placebo and those recruited after the age of 12.25 years started ethinylestradiol at age 14. Main outcome measure Final height. Results 106 participants were recruited, of whom 14 withdrew and 82/92 reached final height. Both oxandrolone and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm (P=0.05, n=48) for late pubertal induction with ethinylestradiol. In the 48 children who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of oxandrolone alone, late induction alone, and oxandrolone plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No cases of virilisation were reported. Conclusion Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial
    Ackroyd, R
    Brown, NJ
    Davis, MF
    Stephenson, TJ
    Marcus, SL
    Stoddard, CJ
    Johnson, AG
    Reed, MWR
    GUT, 2000, 47 (05) : 612 - 617
  • [32] Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
    Ballard, C
    Margallo-Lana, M
    Juszczak, E
    Douglas, S
    Swann, A
    Thomas, A
    O'Brien, J
    Everratt, A
    Sadler, S
    Maddison, C
    Lee, L
    Bannister, C
    Elvish, R
    Jacoby, R
    BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7496): : 874 - 877
  • [33] PREMENSTRUAL SYNDROME - DOUBLE-BLIND CONTROLLED TRIAL OF PROGESTERONE AND PLACEBO
    SAMPSON, GA
    BRITISH JOURNAL OF PSYCHIATRY, 1979, 135 (SEP) : 209 - 215
  • [34] Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
    Lagae, Lieven
    Sullivan, Joseph
    Knupp, Kelly
    Laux, Linda
    Polster, Tilman
    Nikanorova, Marina
    Devinsky, Orrin
    Cross, J. Helen
    Guerrini, Renzo
    Talwar, Dinesh
    Miller, Ian
    Farfel, Gail
    Galer, Bradley S.
    Gammaitoni, Arnold
    Mistry, Arun
    Morrison, Glenn
    Lock, Michael
    Agarwal, Anupam
    Lai, Wyman W.
    Ceulemans, Berten
    Gill, Deepak
    Riney, Kate
    Scheffer, Ingrid
    Buchhalter, Jeffrey
    Carmant, Lionel
    Connolly, Mary
    Nabbout, Rima
    Brandt, Ulrich
    Jacobs-LeVan, Julia
    Mayer, Thomas
    Panzer, Axel
    Pringsheim, Milka
    Stephani, Ulrich
    Wolff, Markus
    Battaglia, Domenica
    Beccaria, Francesca
    Dana, Francesca
    Granata, Tiziana
    Romeo, Antonio
    Striano, Pasquale
    Vigevano, Federico
    Gil-Nagel, Antonio
    San Antonio, Victoria
    Sanchez-Carpintero, Rocio
    Desurkar, Archana
    Hughes, Elaine
    Lyer, Anand
    Philip, Sunny
    Zuberi, Sameer
    Sharp, Gregory
    LANCET, 2019, 394 (10216): : 2243 - 2254
  • [35] Amantadine for treatment of fatigue in Guillain-Barre syndrome:: a randomised, double blind, placebo controlled, crossover trial
    Garssen, MPJ
    Schmitz, PIM
    Merkies, ISJ
    Jacobs, BC
    van der Meché, FGA
    van Doorn, PA
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (01): : 61 - 65
  • [36] Effects of childhood low-dose estrogen on pubertal development in patients with Turner syndrome (TS): Results of a double-blind, randomized, placebo-controlled clinical trial
    Ross, Judith L.
    Quigley, Charmian A.
    Feuilian, Penelope
    Chipman, John J.
    Cutler, Gordon B.
    HORMONE RESEARCH, 2008, 70 : 43 - 43
  • [37] Effect of intravenous S-ketamine on the MAC of sevoflurane: a randomised, placebo-controlled, double-blind clinical trial
    Hamp, T.
    Baron-Stefaniak, J.
    Krammel, M.
    Reiter, B.
    Langauer, A.
    Stimpfl, T.
    Ploechl, W.
    BRITISH JOURNAL OF ANAESTHESIA, 2018, 121 (06) : 1242 - 1248
  • [38] Rituximab treatment in primary Sjogren's syndrome: A double-blind placebo controlled trial
    Meijer, Jiska M.
    Vissink, Arjan
    Meiners, Petra M.
    Spijkervet, Fred K. L.
    Kallenberg, Cees G. M.
    Bootsma, Hendrika
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S430 - S431
  • [39] Randomised, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers
    Dale, JJ
    Ruckley, CV
    Harper, DR
    Gibson, B
    Nelson, EA
    Prescott, RJ
    BRITISH MEDICAL JOURNAL, 1999, 319 (7214): : 875 - 878
  • [40] A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
    Shiina, Akihiro
    Shirayama, Yukihiko
    Niitsu, Tomihisa
    Hashimoto, Tasuku
    Yoshida, Taisuke
    Hasegawa, Tadashi
    Haraguchi, Tadashi
    Kanahara, Nobuhisa
    Shiraishi, Tetsuya
    Fujisaki, Mihisa
    Fukami, Goro
    Nakazato, Michiko
    Iyo, Masaomi
    Hashimoto, Kenji
    ANNALS OF GENERAL PSYCHIATRY, 2010, 9